A Comparison of Mometasone to Advair in Patients With Milder Persistent Asthma

Stopped early · Phase 4

Conditions studied: Asthma

In brief

The research hypothesis for the proposed study asks the question, can Asmanex® demonstrate comparable anti-inflammatory therapeutic efficacy to the combination product, Advair® in control of mild persistent asthma? The purpose is to demonstrate that the anti-inflammatory protection afforded by monotherapy with an inhaled steroid (Asmanex®) is comparable to combination therapy with Advair® 100/50, when measured by this standard methodology (methacholine bronchoprovocation) in subjects with mild persistent asthma.

Key facts

Study ID

NCT00461812

Run by

Johns Hopkins University

People needed

33

Starts

2007-04-01

Expected to finish

2010-01-19

Last updated by the study team

2017-09-20

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• subjects 18 to 65 years of age
• a >2 year history of asthma
• FEV1 > 80% for subjects currently using Advair®.

You may not qualify if…

• severe asthma
• current smokers
• pregnant or breast-feeding women
• other chronic significant illnesses

Where it is running

• Johns Hopkins Asthma and Allergy Center — Baltimore, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.